M. F. Stevens, J. A. Hickman, S. P. Langdon, et al., “Antitumor Activity and Pharmacokinelics in Mice of 8-Carbamoyl-3-Methyl-Imidazo[5.I-d]-l.2.3.5-Lelrazin-4(3H)-One (CCRG 81045; M & B 39831). A Novel Drug with Potential as an Alternative to Dacarbazine,” Cancer Reseach, Vol. 47, 1987, pp. 5846-5852.

has been cited by the following article:

• TITLE: Extended Daily Schedule of Temozolomide in Recurrent Glioblastoma: Single-Institution Report on a Series of 43 Patients

  AUTHORS: Alessandro D’Elia, Vincenza Maiola, Mirena Manucci, Angelo Pichierri, Alessandro Frati, Felice Giangaspero, Maurizio Salvati

  KEYWORDS: Glioblastoma; Recurrence; Progression; Temozolomide; Metronomic Chemotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.2, February 10, 2014

  ABSTRACT: Background: Despite advances in surgical and first-line adjuvant treatment, glioblastoma multiforme (GBM) always recurs as disease natural history. Currently, there is no consensus as to the optimal second-line treatment of recurrent GBM. Patients and Methods: This is a retrospective study of a series of adult patients consecutively treated at a single institution for supratentorial cerebral GBM at first relapse. All patients had previously received the standard concomitant radiochemotherapy protocol as first-line therapy. At recurrence/progression, all patients were treated with a metronomic temozolomide (TMZ) schedule at a daily dosage of 50 mg/m2 of body surface. Radiologic, clinical, and laboratory data were collected for all patients, with a minimum follow-up of 18 months. Results: From January 2010 to June 2011, 43 patients were treated at our facility. A mean of 10 metronomic TMZ cycles (range, 3 - 21) was administered. Radiologically, we observed 2 complete responses (4.6%), 16 partial responses (37.2%), 18 stable disease (41.9%) and 7 progressive disease (16.3%). Steroids administration was safely tapered in 23 patients (53.5%). Karnofsky-Performance-Status (KPS) results improved in 20 patients (46.5%), stabilized in 20 (46.5%), and worsened in 3 patients (7.0%), with a mean KPS score increased from 65.1 at baseline to 75.3 at follow-up. Six-month progression-free survival was 53.5. One year after recurrence/progression diagnosis, 22 patients were still alive, with a 1-year overall survival rate of 51.6%. Conclusions: The proposed TMZ schedule seems a safe and effective option for patients with recurrent GBM, with high radiologic response rates and good clinical impact. Strict clinical observation of patients may enable obtaining better results than those already present in the literature and further investigation appears auspicable.